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SaBACKGROUND Sudden arrhythmic death syndrome (SADS) describes a sudden death with negative autopsy and
toxicological analysis. Cardiac genetic disease is a likely etiology.
OBJECTIVES This study investigated the clinical utility and combined yield of post-mortem genetic testing (molecular
autopsy) in cases of SADS and comprehensive clinical evaluation of surviving relatives.
METHODS We evaluated 302 expertly validated SADS cases with suitable DNA (median age: 24 years; 65% males) who
underwent next-generation sequencing using an extended panel of 77 primary electrical disorder and cardiomyopathy
genes. Pathogenic and likely pathogenic variants were classiﬁed using American College of Medical Genetics (ACMG)
consensus guidelines. The yield of combined molecular autopsy and clinical evaluation in 82 surviving families was
evaluated. A gene-level rare variant association analysis was conducted in SADS cases versus controls.
RESULTS A clinically actionable pathogenic or likely pathogenic variant was identiﬁed in 40 of 302 cases (13%). The
main etiologies established were catecholaminergic polymorphic ventricular tachycardia and long QT syndrome (17 [6%]
and 11 [4%], respectively). Gene-based rare variants association analysis showed enrichment of rare predicted deleterious
variants in RYR2 (p ¼ 5  10-5). Combining molecular autopsy with clinical evaluation in surviving families increased
diagnostic yield from 26% to 39%.
CONCLUSIONS Molecular autopsy for electrical disorder and cardiomyopathy genes, using ACMG guidelines for
variant classiﬁcation, identiﬁed a modest but realistic yield in SADS. Our data highlighted the predominant role of
catecholaminergic polymorphic ventricular tachycardia and long QT syndrome, especially the RYR2 gene, as well as the
minimal yield from other genes. Furthermore, we showed the enhanced utility of combined clinical and genetic
evaluation. (J Am Coll Cardiol 2017;69:2134–45) © 2017 The Authors. Published by Elsevier on behalf of the American
College of Cardiology Foundation. This is an open access article under the CC BY license (http://creativecommons.org/
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AB BR E V I A T I O N S
AND ACRONYM S
ACM = arrhythmogenic
cardiomyopathy
ACMG = American College of
Medical Genetics
BrS = Brugada syndrome
CPVT = catecholaminergic
polymorphic ventricular
tachycardia
LQTS = long QT syndrome
MAF = minor allele frequency
SADS = sudden arrhythmic
death syndrome
SCD = sudden cardiac death
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2135S udden cardiac death (SCD) in the young is adevastating event. The annual incidence in the1- to 35-year-old age group is estimated at 1.3
to 2.8 per 100,000 (1). Autopsies in younger SCD vic-
tims lead to a diagnosis of structural cardiac disease
in the majority. Yet, in 30% to 40% of cases, the cause
remains elusive despite toxicological and histopatho-
logic analysis (1,2). A proportion is expected to have
suffered arrhythmic death and is referred to as
succumbing from sudden arrhythmic death syndrome
(SADS) (3,4). SADS is caused, in part, by primary elec-
trical disorders such as long QT syndrome (LQTS), Bru-
gada syndrome (BrS), and catecholaminergic
polymorphic ventricular tachycardia (CPVT), which
are associated with a structurally normal heart (5,6).SEE PAGE 2146
VUS = variant of unknown
ﬁcancePost-mortem testing of the genes underlying
primary electrical disorders in cases of SADS (the
“molecular autopsy”) allows for ascertainment of the
genetic cause (7,8). This may inform clinical and
genetic evaluation of surviving relatives for SCD
prevention (9). Early case series focused on 4 main
genes (KCNQ1, KCNH2, SCN5A, and RYR2). Relatively
small studies have interrogated extended gene panels
including cardiomyopathy-associated genes by next-
generation sequencing. The yield varied widely due
to variation in variant-calling (2,8,10). More recently,
Bagnall et al. (1) performed genetic testing in 113
unexplained SCDs (i.e., SADS) and the authors
reported a “clinically relevant” cardiac genetic
variant in 27%. A deﬁnite clinical diagnosis (pre-
dominantly LQTS and CPVT) was established in 12 of
91 families (13%) who underwent clinical screening.
Critically, however, recent large-scale genetic
studies have identiﬁed widespread low-frequency
genetic variation in cardiac genes that may
confound results (11). This necessitates robust
ﬁltering strategies in the analysis of candidate vari-
ants. Furthermore, there has been limited evaluation
of the combined utility of molecular autopsy in
clinical and genetic evaluation of the family.
We here investigated an extended panel of 77
primary electrical disorder and cardiomyopathyYoung (to Drs. Raju, Papadakis, Mellor, Sharma, Sheppard, and Behr); the Bri
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(n ¼ 302) thus far. By applying stringent
American College of Medical Genetics (ACMG)
consensus guidelines for variant classiﬁca-
tion (12), we identiﬁed clinically actionable
genetic variants and deduced a likely realistic
contribution of the tested genes to SADS. We
then evaluated the role of combined post-
mortem genetic testing and clinical evalua-
tion in surviving relatives.
METHODS
SADS was deﬁned as an unexplained death
without prior cardiovascular disease within 1
h of symptom onset or an unwitnessed death
with the individual being seen in good
health within 24 h of death; no cause of death was
identiﬁable on comprehensive coronial and cardiac
autopsy or on toxicological analyses (13). Cases with
structural disease (e.g., cardiomyopathy; n ¼ 53) or
nonspeciﬁc changes (e.g., left ventricular hypertro-
phy without disarray or idiopathic ﬁbrosis; n ¼ 29) at
autopsy were excluded from the study. Data
including clinical history, prior symptoms, circum-
stance of death, and family history were collected by
direct contact with next of kin, and from coroner
and pathologist reports. In total, 302 of 384 potential
cases (79%) with suitable deoxyribonucleic acid
(DNA) were included. Cohort 1 consisted of 2
population-based coronial series: Cardiac Inherited
Disease Registry, Auckland, New Zealand, 2000 to
2009 (n ¼ 38) (14,15); and the SCD Registry,
Denmark, 2000 to 2006, (n ¼ 27) (16). Cohort 1 was
also drawn from: consecutive referrals for autopsy
(Royal Brompton Hospital, United Kingdom 2007 to
2011; n ¼ 28); Shefﬁeld Children’s Hospital (United
Kingdom 1985 to 2001; n ¼ 20) and consecutive
referrals for familial cardiac evaluation (St. George’s
and Lewisham Hospitals, United Kingdom, 2009 to
2011; n ¼ 30); and Academic Medical Centre,
Netherlands 1995 to 2011 (n ¼ 10). Cohort 2 consisted
of 149 consecutive referrals for autopsy at St.
George’s Hospital, United Kingdom, 2012 to 2015.
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2136The study was approved by Research Ethics Service
Wandsworth.
The control cohort was derived from 1,158 adult
volunteers recruited prospectively as part of the UK
Digital Heart Project. Cardiac magnetic resonance
imaging and an electrocardiogram (ECG) were normal
in all subjects and there was no family history of
cardiac disease. The study was approved by the
National Health Service of England Research Ethics
Committee.
NEXT-GENERATION SEQUENCING. Subjects’ DNA
samples were sequenced using targeted high-
throughput sequencing. Target regions were
captured by in-solution hybridization target capture,
using the SureSelect system (Aligent Technologies,
Santa Clara, California) for cohort 1 or the Illumina
TruSight Cardio system (Illumina, San Diego, Cali-
fornia) for cohort 2 and controls. For SureSelect
capture, custom hybridization-capture probes were
designed using the eArray platform (Aligent
Technologies) to target 201 genes implicated in car-
diovascular disease. Ribonucleic acid baits targeted
all exons of all Ensembl (v54) (17) transcripts,
including untranslated regions, with a 100-bp exten-
sion into adjacent introns. The TruSight Cardio Kit
consists of comprehensive coverage of 174 genes
(coding sequence region only) with known associa-
tions to 17 inherited cardiac conditions (18). Libraries
were prepared per manufacturer’s instructions and
sequenced on the Illumina HiSeq (cohort 1) or Next-
Seq (cohort 2 and controls). We analyzed 77 genes
tested by both systems that have been previously
associated with primary electrical diseases or cardio-
myopathies (Online Table 1).
All the samples (i.e., cohorts 1, 2, and controls)
were processed together. Low quality (Q<20, window
size 5) reads/bases were trimmed and read quality
assessed. High-quality reads were mapped to UCSC
GRCh37/hg19 reference genome. Next-generation
sequencing was used to mark duplicate reads,
realign locally around indels, and recalibrate base
quality scores according to best practices. Alignment
summary metrics and coverage and callability metrics
were generated. A base was considered “callable” if
sequenced with minimum read depth¼ 10x, base
quality$20, and mapping quality$10. Target base
callability of >90% was achieved in 98% of samples
overall and in 92%, 95%, and 100% of samples from
cohort 1, 2, and controls, respectively. Gene level
callability is shown in Online Table 2. Exons with
callability <80% are shown in Online Table 3. Genome
Analysis Toolkit v3.2 HaplotypeCaller was used to call
variants from reads mapped with quality$8, and forjoint variant calling. Indels with quality by depth
<2.0, ReadPosRankSum <20.0, FisherStrand >200.0
and coefﬁcient of inbreeding 0.8 were ﬁltered out.
Single nucleotide polymorphisms with quality by
depth <2.0, FisherStrand >60.0, RMSMappingQuality
<40.0, mapping quality rank sum <12.5, and Read-
PosRankSum <8.0 were ﬁltered out. Variants were
annotated using ANNOVAR (19).
VARIANT FILTERING, CLASSIFICATION, AND ANALYSIS.
Variants with a minor allele frequency (MAF) >1 in
10,000 in the Exome Aggregation Consortium (ExAC)
(20), synonymous variants not located at splice sites
and nontruncating variants in TTN were excluded
(21). Variants that remained were classiﬁed manually
as pathogenic, likely pathogenic, or as variant of un-
known signiﬁcance (VUS) using the recent stringent
ACMG consensus statement guidelines (12). Variants
were checked for prior reports in the literature and in-
house databases of primary electrical diseases and
hereditary cardiomyopathies at the Academic Medical
Centre. The reported phenotype (including diagnosis,
ECGs, and cardiac symptoms), the presence of cose-
gregation data, and the mode of inheritance were
critically assessed. Variants were then adjudicated by
2 further independent observers and agreed by
consensus.
Statistical enrichment of rare variants was
analyzed for in SADS cases versus controls using the
sequence kernel association test (22) as implemented
in RVTESTS (rare variant tests) (23). We restricted the
analysis to rare variants (MAF <1 in 10,000 in ExAC)
predicted to be deleterious by a Combined
Annotation-Dependent Depletion (24) score >25 to
decrease genetic background noise and enrich for
variants that could potentially be disease causing.
SADS cases and controls of non-European descent
were excluded from the analysis. As a negative con-
trol, we performed the gene-based analysis using
only rare synonymous variants not predicted to
change the protein. Bonferroni correction for multi-
ple testing was used to deﬁne statistical signiﬁcance
thresholds. We tested 77 genes and 1 phenotype
(SADS): single-gene tests were considered signiﬁcant
if p values were < a ¼ 0.05/77 (p < 6.5  10-4).
GENOTYPE-PHENOTYPE CORRELATIONS. We used
single and multiple logistic regression models to
identify independent predictors of a positive genetic
test deﬁned as a pathogenic or likely pathogenic
variant per ACMG guidelines. Variables included in
the model were: sex; age category (#35 years and >35
years); circumstances of death (adrenergic: exercise
and extreme emotion; non-adrenergic: sleep, rest,
and light activity); prior symptoms (transient loss of
TABLE 1 Demographic and Genotype-Phenotype Correlations of the SADS Cohort
SADS
(n ¼ 302)
SADS and Negative
Genetic Testing
(n ¼ 262)*
SADS and Positive
Genetic Testing
(n ¼ 40)*
SADS Without Positive
Genetic Testing for
a RYR2 Variant
(n ¼ 285)*
SADS and Positive
Genetic Testing for
a RYR2 Variant
(n ¼ 17)* p Value†
Age at death, yrs 24 (17–33) 25 (18–33) 20 (11–32) 25 (18–34) 13 (8–18) 0.0004
Male 197/302 (65) 172/262 (66) 25/40 (62) 183/285 (64) 14/17 (82) 0.1918
Circumstances of death‡
Exercise and extreme emotion 30/262 (11) 20/228 (9) 10/34 (29) 21/245 (9) 9/17 (53) <0.0001
Sleep and rest 188/262 (72) 170/228 (75) 18/34 (53) 183/245 (75) 5/17 (29) 0.0002
Light activity 44/262 (17) 38/228 (17) 6/34 (18) 41/245 (17) 3/17 (18) 1.0000
Symptoms before death‡
Syncope and/or seizures 50/268 (18) 40/235 (17) 10/33 (30) 43/253 (17) 7/15 (47) 0.0101
Other§ 18/268 (7) 16/235 (7) 2/33 (6) 17/253 (7) 1/15 (7) 1.0000
None 200/268 (75) 179/235 (76) 21/33 (64) 193/253 (76) 7/15 (47) 0.0269
Family history of SCD <50 yrs of age‡ 19/269 (7) 12/233 (5) 7/36 (19) 16/254 (6) 3/15 (20) 0.0791
Values are median (interquartile range) or n/N (%). *Positive outcome was deﬁned as a pathogenic or likely pathogenic variant per the ACMG guidelines (12). †p values refer to the following
comparison: positive genetic testing RYR2 (n ¼ 17) versus no positive RYR2 test (n ¼ 285). ‡Note missing data for these parameters and that percentages are based on nonmissing data.
§Includes palpitations, shortness of breath, and chest pain.
ACMG ¼ American College of Medical Genetics; SADS ¼ sudden arrhythmic death syndrome; SCD ¼ sudden cardiac death.
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2137consciousness: seizures and syncope; other: palpita-
tions and chest pain); and a family history of SCD <50
years of age. Comparison was performed using the
Student t test for normally distributed continuous
variables, the Mann-Whitney U test for non-normally
distributed continuous variables, and the chi-square
or Fisher’s exact test, as suitable, for categorical
variables. All statistical analyses were performed
using R (version 3.2.1.), and a p < 0.05 was used to
indicate statistical signiﬁcance.
FAMILY STUDIES. Where families of SADS cases had
undergone clinical evaluation and/or genetic testing
(n ¼ 82) data on clinical testing performed, clinical
diagnoses and genetic testing results were gathered
where available. Diagnoses were based on the current
consensus guidelines (4,25). We then assessed the
independent value of molecular autopsy and familial
evaluation for a familial diagnosis.
RESULTS
Demographic and clinical characteristics of all sub-
jects are presented in Table 1. In total, 302 sudden
unexplained death patients were included (197 males
and 105 females; median age: 24 years [interquartile
range: 17 to 33 years; range: 1 to 64 years]) (Figure 1A).
Most were of European descent (88%) and 235 died
before or at the age of 35 years (78%). The most
prevalent circumstances of death were during sleep
(43%) or rest (29%) with death occurring during
exercise or extreme emotion in 10% and 1.5%,
respectively (Figure 1B). A family history of sudden
death before the age of 50 years was present in 7.1%
of subjects. In 18%, a personal history of syncope orseizure was reported (Figure 1C). Importantly, 24
subjects had consulted a cardiologist or general
practitioner regarding these symptoms. Twenty-one
subjects (7%) were diagnosed either with epilepsy or
had a previous history of epilepsy; 7 patients had type
1 diabetes mellitus and were being treated with
insulin from early childhood or adolescence. Among
the 105 female cases, 7 died suddenly during the
post-partum period.
Genetic testing was performed (Central Illustration)
and there remained a total of 288 variants (MAF <1 in
10,000) in 55 different genes after variant ﬁltering in
the 302 SADS cases (Figure 2). In 132 patients (44%),
no rare variant was identiﬁed. Gene level callability
indicated only minor deﬁcits or differences in
coverage between cohorts (Online Table 2). Manual
curation against ACMG guidelines yielded 20 patho-
genic and 20 likely pathogenic variants with an
overall yield of 13% (40 of 302 patients) (Table 2). Age
distribution was as follows: 1 to 18 years (n ¼ 18;
20%); 19 to 35 years (n ¼ 13; 9%); 36 to 65 years (n ¼ 8;
12%); and 1 age unknown. No subject carried more
than 1 pathogenic or likely pathogenic variant.
Nineteen pathogenic and 15 likely pathogenic vari-
ants resided in the primary electrical disorder genes,
mainly RYR2, KCNQ1, KCNH2, and SCN5A. In the
cardiomyopathy genes, we found 1 pathogenic
variant in PLN and 5 likely pathogenic variants in
TTN (n ¼ 3), PKP2 (n ¼ 1), and MYH7 (n ¼ 1). We
identiﬁed a pathogenic variant in 4 subjects >35
years of age; KCNQ1, KCNH2, SCN5A, and RYR2.
Additionally, a likely pathogenic variant was identi-
ﬁed in KCNQ1, KCNH2, TTN, and MYH7 in this
age category. Furthermore, we found a pathogenic
FIGURE 1 SADS: Demographic and Clinical Characterization
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Sudden arrhythmic death syndrome (SADS) (A) more often affected males and individuals 35 years and younger; (B) 72% of SADS deaths
occurred during sleep or rest. (C) Whereas three-quarters exhibited no symptoms before death, 13% had a history of seizures.
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2138variant in RYR2 and KCNH2 in 2 of 7 post-partum
cases. Figure 2 illustrates the signiﬁcantly higher
prevalence of VUS in cardiomyopathy genes (97%)
compared to primary electrical disease genes (71%)
and the highly unfavorable ratio of VUS to pathogenic
and likely pathogenic variants in the cardiomyopathy
genes (28:1).
All 21 cases with epilepsy had a long-term history
of syncope and seizures before death. Genetic testing
identiﬁed a likely cause of death in 5 (24%): 2 path-
ogenic and 2 likely pathogenic variants in RYR2 and
1 pathogenic variant in KCNH2.
Gene-based rare variant association analysis was
undertaken in 270 SADS cases and 508 healthy con-
trols (226 males and 282 females; mean age 42.00 
13.42 years; range 19 to 77 years) of European descent.
Fifty-seven genes that carried 1 or more variants with
MAF <1 in 10,000 and Combined Annotation-Dependent Depletion score >25 were analyzed
(Online Table 4). Only RYR2 displayed an enrichment
of rare variants in cases compared to controls at our
pre-speciﬁed statistical signiﬁcance threshold
(p ¼ 6.5  10–4). To ensure that this result was not a
consequence of systematic sequencing differences
between cases and controls, we performed the same
analysis using only rare synonymous variants, which
did not uncover any differences (p ¼ 0.89).
Predictors of a positive genetic test are listed in
Table 3. In the single regression model, both adren-
ergic circumstances of death (exercise and extreme
emotion; odds ratio [OR]: 4.33; 95% conﬁdence
interval [CI]: 1.77 to 10.21; p ¼ 0.0009), and a positive
family history of SCD <50 years (OR: 4.45; 95% CI: 1.55
to 12.00; p ¼ 0.004), were associated with a positive
genetic test. In the multiple logistic regression model,
adrenergic circumstances of death (exercise and
CENTRAL ILLUSTRATION Sudden Arrhythmic Death Syndrome: Genetic Testing and Clinical Screening
Lahrouchi, N. et al. J Am Coll Cardiol. 2017;69(17):2134–45.
(A to E) Genetic testing via next-generation sequencing in 302 sudden arrhythmic death syndrome (SADS) cases identiﬁed pathogenic and likely pathogenic variants in
13% of cases. Clinical screening of relatives in 82 families found 35 relatives from 21 families with a clinical diagnosis of a primary electrical disease: Brugada syndrome
(BrS); catecholaminergic polymorphic ventricular tachycardia (CPVT); and long-QT syndrome (LQTS); there was overlap between molecular and clinical diagnosis
in 7 families. Combining molecular autopsy with clinical evaluation increased diagnostic yield in surviving families to 39%. VUS ¼ variant of unknown signiﬁcance.
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2139extreme emotion; OR: 4.38; 95% CI: 1.63 to 11.28;
p ¼ 0.002) was independently associated with a pos-
itive genetic test. Neither sex nor age category at
death (#35 years or >35 years) were associated with a
positive genetic test. Using age as a quantitative trait
in the analyses did not change the results.
Genotype-phenotype correlations in SADS cases
with RYR2 variants are shown in Table 1. Since a
substantial number of SADS cases (n ¼ 17) had
pathogenic/likely pathogenic variants in RYR2, we
compared their characteristics with the remaining
patients. RYR2 cases were signiﬁcantly younger
(median age 13 years versus 25 years; p ¼ 0.0004) incomparison to cases with negative RYR2 testing (n ¼
285) and death occurred more often during exercise
or extreme emotion (9 of 17 vs. 21 of 245; p < 0.0001).
Of the 4 SADS subjects who died suddenly during
extreme emotion, all carried a pathogenic or likely
pathogenic variant in RYR2. There was no statistically
signiﬁcant difference in family history of sudden
death between RYR2 cases as compared to the rest of
the SADS cohort (3 of 15 vs. 16 of 254; p ¼ 0.0791).
Cardiac evaluation was performed in 282 relatives
from 82 SADS families (Central Illustration). Family
members underwent 12-lead ECG (n ¼ 282), signal-
averaged ECG (n ¼ 85), exercise testing (n ¼ 192),
FIGURE 2 ACMG Classiﬁcation of Variants
200
150
Nu
m
be
r o
f V
ar
ia
nt
s
100
50
Primary electrical disease
Ratio of VUS to P and LP variants
2.4:1
Ratio of VUS to P and LP variants
28:1
Gene category
19 15
82
Cardiomyopathy
1 5
166
Pathogenic (P) Likely Pathogenic (LP) Variant of Unknown Significance (VUS)
0
A signiﬁcantly higher prevalence of variants of unknown signiﬁcance (VUS) was found in cardiomyopathy genes compared to primary electrical
disease genes, and there was a highly unfavorable ratio of VUS to pathogenic and likely pathogenic variants in the cardiomyopathy genes (28:1)
per the American College of Medical Genetics (ACMG) classiﬁcation of 288 variants in 170 cases. P ¼ pathogenic; LP ¼ likely pathogenic.
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214024-h Holter monitoring (n ¼ 178), transthoracic
2-dimensional echocardiograms (n ¼ 206), ajmaline/
ﬂecainide testing (n ¼ 101), and cardiac magnetic
resonance imaging (n ¼ 41) in expert centers. Thirty-
ﬁve relatives (12%) from 21 (26%) families were clin-
ically diagnosed with a primary electrical disease: BrS
in 20 relatives from 14 families (17%); CPVT in 12 from
4 families (5%); and LQTS in 5 relatives from 3 fam-
ilies (4%). Relatives received treatment per current
guidelines (4).
We then considered the added diagnostic value of
combining clinical evaluation of family members and
post-mortem genetic testing in the SADS case
(Central Illustration). Molecular autopsy had identi-
ﬁed a pathogenic or likely pathogenic variant in 18
of 82 families (22%). Relevant pedigrees are shown
in the Online Appendix. Eight variants (10%) were
considered diagnostic for CPVT, 5 (6%) for LQTS, 2
for BrS (2%), and 3 (3.5%) for cardiomyopathy. An
overlap was observed in 7 of 82 families (8.5%)
where molecular autopsy and clinical evaluation of
family members resulted in the same diagnosis:
CPVT in 4, LQTS in 2, and BrS in 1 (see Online
Figure 1, Family 6 for segregation of SCN5A
variant). Therefore, an additive independent yield of
molecular autopsy was seen in 11 of 82 families
(13%). In 14 families (17%), clinical screening ofrelatives identiﬁed a clinical diagnosis that was not
conﬁrmed by post-mortem genetic screening in the
index SADS case; 13 of these were diagnosed with
BrS whereas 1 family was diagnosed with LQTS.
Overall, the combined diagnostic yield of clinical
evaluation of family members and molecular au-
topsy in the index SADS case was 32 of 82 families
(39%; 95% CI: 28% to 49%). In 2 SADS cases, com-
bined clinical and genetic screening of surviving
relatives led to an upgrade of a RYR2 variant ACMG
classiﬁcation from likely pathogenic to pathogenic
because of de novo inheritance in 1 family (Online
Figure 1, Family 3) and clear cosegregation with
exertional arrhythmia in the other (Online Figure 1,
Family 5). In a 4-year-old SADS case, a homozygous
nonsense variant was identiﬁed in KCNQ1.
Re-examination of the medical history conﬁrmed
that the patients’ parents were consanguineous and
that the deceased had a history of congenital
sensorineural deafness, conﬁrming a clinical diag-
nosis of Jervell and Lange-Nielsen syndrome (Online
Figure 1, Family 1).
DISCUSSION
We report, to our knowledge, the largest study of
molecular autopsy and its clinical utility in a set of
TABLE 2 Overview of Pathogenic and Likely Pathogenic Variants in SADS Cohort
Case
Age at
Death
(yrs) Sex
Circumstances
of Death
Symptoms
Before Death Gene Chr Start Ref Alt cDNA change
Amino Acid
Change*
ACMG
Classiﬁcation† ACMG Criteria†
P1 31 M NA NA KCNH2 7 150671971 G C c.C135G p.N45K LP PM1,PM2,PM5,PP3
P2 22 M Rest None KCNH2 7 150655191 A G c.T872C p.M291T LP PS4,PM2
P3 19 F Sleep None KCNH2 7 150649550 G A c.C1520T p.P507L P PM1,PM2,PM5,PP3
P4 44 F Rest None KCNH2 7 150649880 C T c.G1190A p.R397H LP PS3,PM5,PP3
P5 22 F Sleep None KCNH2 7 150647481 G A c.C2173T p.Q725X P PVS1,PM2,PP3
P6 22 F NA NA KCNH2 7 150644460 GC G c.3107_3108C p.G1036AfsX21 P PVS1,PM2,PP1,PP3
P7 39 F Sleep Seizures KCNH2 7 150648593 C T c.G1888A p.V630I P PS4,PM1,PM5,PP3,PP5
P8 10 M Light
activity
Seizures KCNQ1 11 2466615 C G c.C287G p.T96R LP PS3,PM2
P9 57 M Sleep None KCNQ1 11 2610045 C T c.C1354T p.R452W LP PS4,PM5,PP3
P10 42 F Sleep None KCNQ1 11 2797262 C T c.C1663T p.R555C P PS3,PS4,PP3
P11 4 F Light
activity
NA KCNQ1 11 2604712 G A c.G969A
(homozygous)
p.W323X
(homozygous)
P PVS1,PM2,PM3,PP3
P12 1 M Sleep None CACNA1C 12 2789725 G GC c.5608_5608delinsGC p.Q1872PfsX24 LP PVS1,PM2
P13 20 M Sleep None RYR2 1 237586538 G A c.G995A p.R332Q P PS4,PM1,PM2,PM5,PP3
P14 18 M Extreme
emotion
Syncope RYR2 1 237608789 G A c.G1259A p.R420Q P PS4,PS3,PM1,PM2,
PM5,PP3
P15 17 M Exercise None RYR2 1 237617856 A C c.A1458C p.Q486H LP PM2,PP3,PP4‡
P16 15 M Exercise Seizures RYR2 1 237754262 C T c.C4130T p.A1377V LP PM2,PP3,PP4‡
P17 12 M Exercise None RYR2 1 237777676 G A c.G5248A p.G1750R LP PM2,PP3,PP4‡
P18 8 M Exercise None RYR2 1 237794789 A G c.A6503G p.H2168R LP PM2,PM5,PP3,PP4
P19 12 F Light
activity
Syncope RYR2 1 237801693 T G c.T6829G p.C2277G LP PM1,PM2,PM5,PP3
P20 6 M Exercise Syncope RYR2 1 237804283 G A c.G7202A p.R2401H P PS4,PM1,PM2,PM5,PP3
P21 11 M Extreme
emotion
None RYR2 1 237870332 G A c.G9664A p.A3222T LP PM2,PM6,PP2,PP3
P22 22 F Extreme
emotion
NA RYR2 1 237538090 C T c.C458T p.T153I P PS4,PM1,PP3‡
P23 24 M Rest None RYR2 1 237538090 C T c.C458T p.T153I P PS4,PM1,PP3‡
P24 18 M Rest None RYR2 1 237886554 C G c.C10681G p.L3561V LP PM1,PM2,PP3‡
P25 8 M Extreme
emotion
Seizures RYR2 1 237942026 G A c.G11836A p.G3946S P PS4,PM1,PM2,PM5,PP3
P26 3 F Rest NA RYR2 1 237947016 A G c.A12004G p.M4002V P PS2,PM1,PM2,PM5,PP3
P27 13 M Sleep Seizures RYR2 1 237947164 C T c.C12152T p.A4051V LP PM1,PM2,PP3
P28 6 M Light
activity
Syncope RYR2 1 237957170 C T c.C13786T p.P4596S P PM1,PM2,PP1,PP3,PP4
P29 41 M Light
activity
Chest pain RYR2 1 237957207 G A c.G13823A p.R4608Q P PS4,PM1,PM2,PM5,
PP1,PP3
P30 2 M Sleep None SCN5A 3 38627337 G A c.C2632T p.R878C P PS4,PS3,PM2,PM5,PP3
P31 1 M Sleep None SCN5A 3 38620964 C T c.G3248A p.G1083D LP PS4,PM2
P32 39 M NA None SCN5A 3 38671833 G A c.C361T p.R121W P PS3,PS4,PM2,PP1,PP3
P33 24 F Light
activity
None SCN5A 3 38655264 G A c.C673T p.R225W P PS3,PS4
P34 21 F NA NA SCN1B 19 35524731 G A c.G536A p.W179X P PVS1,PS1,PS4,PS3
P35 55 F Rest None TTN 2 179391915 C A c.G80605T p.G26869X LP PVS1,PM2
P36 33 F NA Seizures TTN 2 179640969 C T c.G5484A p.W1828X LP PVS1, PS4‡
P37 NA F NA NA TTN 2 179640969 C T c.G5484A p.W1828X LP PVS1, PS4‡
P38 32 M Rest None PLN 6 118880200 T G c.T116G p.L39X P PVS1,PS4,PP5
P39 22 M Exercise None PKP2 12 32975414 CT C c.1825_1826G p.R609GfsX3 LP PVS1,PM2
P40 54 M Sleep Palpitations MYH7 14 23886806 C T c.G4259A p.R1420Q LP PS4,PM2,PM5,PP3
*The following transcripts were used: CACNA1C:NM_001167625; KCNH2:NM_000238; KCNQ1:NM_000218; PKP2:NM_001005242; PLN:NM_002667; RYR2:NM_001035; SCN1B:NM_199037; SCN5A:
NM_000335; TTN:NM_003319. †See ACMG guidelines (12) for further information on classiﬁcation criteria. ‡For these variants, 1 criterion was moved to a higher weight using consensus and professional
judgment of 3 observers, in line with the ACMG guidelines.
Alt ¼ alternate allele; cDNA ¼ coding DNA; Chr ¼ chromosome; LP ¼ likely pathogenic; NA ¼ not available; P ¼ pathogenic; Ref ¼ reference allele; other abbreviations as in Table 1.
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TABLE 3 Association of Predictors and Positive Post-Mortem Genetic Testing
Predictor
Positive Genetic Testing Multiple Regression Model Single Regression Model
Predictor
Present (%)
Predictor
Absent (%) OR (95% CI) p Value OR (95% CI) p Value
Death #35 yrs of age 13 12 NA NA 1.08 (0.49–2.64) 0.851
Male 1 14 NA NA 0.87 (0.44–1.77) 0.697
Death during adrenergic circumstances
(exercise and extreme emotion)
33 10 4.38 (1.63–11.28) 0.002 4.33 (1.77–10.21) 0.0009
TLOC (seizures and syncope) before death 20 11 2.42 (0.94–5.90) 0.057 2.12 (0.90–4.70) 0.071
Family history of SCD <50 yrs of age 37 12 3.16 (0.84–10.52) 0.069 4.45 (1.55–12.00) 0.004
CI ¼ conﬁdence interval; OR ¼ odds ratio; TLOC ¼ transient loss of consciousness; other abbreviations as in Tables 1 and 2.
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large panel of 77 genes using next-generation
sequencing. Applying highly stringent criteria as
indicated by the ACMG guidelines, we identiﬁed a
pathogenic or likely pathogenic variant, which we
consider actionable, in 13% of cases. The main causes
of death established through genetic testing were
CPVT and LQTS. This was further supported by the
case-control rare variant association analysis we
conducted, which demonstrated enrichment of rare
predicted deleterious variants in the RYR2 gene
responsible for CPVT. We combined molecular
autopsy with clinical evaluation in surviving family
members and demonstrated the added value of such
an approach.
COMPARISON WITH PREVIOUS NEXT-GENERATION
SEQUENCING MOLECULAR AUTOPSY STUDIES. Our
study identiﬁed a modest, though likely more real-
istic, yield of genetic testing (13%) in SADS cases,
compared to previous studies reporting a yield of
27% to 32% (26–28). These earlier studies had relied
strongly on the application of MAF thresholds and
estimation of pathogenicity by computational
approaches in determining yield. Often the MAF
threshold used had been too lenient when the
Mendelian nature of the underlying disorders is
considered and that variants that contribute to such
disorders are expected to be very rare in the general
population. In our study, besides applying a strin-
gent MAF threshold of 1 in 10,000, which we have
previously validated as appropriate for these condi-
tions (11), we strove to achieve robust and rigorous
variant classiﬁcation by evaluating each variant
against the ACMG variant classiﬁcation guidelines.
Admissible evidence included family segregation
data; population data (such as novelty); observations
in multiple, unrelated, clinically affected in-
dividuals; functional evidence; and concordancebetween mutation type and genetic mechanism of
the disease. Despite this there is still an element of
subjectivity that may result in variability of ﬁnal
assignment by different laboratories. Speciﬁcally,
Bagnall et al. (1) reported a 27% yield of “clinically
relevant” cardiac genetic variants. Importantly,
clinical relevance was partially based on in silico
prediction tools, which may have led to an over-
estimation of the yield. Indeed, our lower yield of
genetic testing is similar to that found in a previous
smaller study that reported an overall yield of 7%;
this study tested a comparable number of genes and
also applied ACMG guidelines (10).
Our study found a likely pathogenic or pathogenic
RYR2 variant in 17 patients (6%) in whom death
occurred at a signiﬁcantly younger age and more
often during exercise or extreme emotion. This was
consistent with our previous characterization of SADS
cases that asserted that CPVT was an important cause
of death in the young (29). The predominant role of
RYR2 was further illustrated by enrichment of rare,
highly deleterious RYR2 variants in SADS cases
compared to controls.
A subanalysis of 82 families showed that
combining molecular autopsy with comprehensive
clinical screening of surviving relatives increased
the diagnostic yield to 39% indicating the potential
complementary value of both approaches when
undertaken systematically hand-in-hand (4,9). Of 14
families with a negative molecular autopsy, clinical
assessment of relatives uncovered a diagnosis of BrS
in 13 cases. These diagnoses were in keeping with
guidelines for investigation of SADS families (4) and
the recent consensus document on diagnosis in BrS
(25). The proper role of provocation testing in mak-
ing these diagnoses does, however, require further
clariﬁcation (25). Genetic variation in SCN5A is
found in only w20% of BrS cases and, although
variants in other genes have been implicated, these
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complex inheritance has been proposed for the dis-
order (5,30). Thus, the diagnosis rests on clinical
evaluation.
Some of the previous post-mortem genetic studies
have only included SADS patients who were <35 years
of age (1,2,8). However, our previous work has shown
no signiﬁcant difference between the characteristics
of younger and older adults with SADS (29). We
included SADS cases from 35 to 65 years of age and
identiﬁed a pathogenic or likely pathogenic variant in
7. In 1 case, the family history included 2 additional
SADS cases (death at ages 14 and 41 years old,
respectively) with post-mortem DNA available
(Online Figure 1, Family 10). The RYR2 variant iden-
tiﬁed in the proband segregated perfectly in this
family and identiﬁed multiple clinically affected and
living patients requiring treatment per current CPVT
guidelines. In line with these data, age was not an
independent predictor of a pathogenic or likely
pathogenic variant in the logistic regression model
(Table 3). Therefore, our data indicates a role for
molecular autopsy beyond 35 years of age (4,9),
although these results could have been biased. Older
SCDs are less likely to be referred for autopsy, and
those who are referred may tend to have a family
history of SCD and, thus, be enriched for genetic risk.
Furthermore, the limited number of patients >50
years old included in this study probably resulted in a
lack of power to detect a difference in this age
category.
WARNING SYMPTOMS BEFORE DEATH. One in 5
subjects had experienced a syncope or seizure before
death and 24 were seen by a physician for these
symptoms. In 2 children in whom we identiﬁed a
pathogenic variant in RYR2, an antemortem resting
ECG had shown no abnormalities. Unfortunately, no
exercise testing had been performed. In one-quarter
of cases diagnosed with epilepsy, molecular autopsy
identiﬁed a likely cause of death, consistent with
previous studies indicating that CPVT or LQTS
patients can be misdiagnosed with epilepsy and
drug-resistant epilepsy (31). These data emphasized
the importance of thorough clinical and cardiac
examination, including exercise testing of patients
presenting with syncope or seizures, especially
during exercise (32).
CARDIOMYOPATHY-ASSOCIATED VARIANTS IN
SADS. The signiﬁcance of the cardiomyopathy-
associated genes in SADS with normal cardiac
autopsy is largely unexplored. Previous studies
that expanded the number of genes in molecularautopsy panels uncovered a large number of car-
diomyopathic rare variants that appeared to enhance
the overall yield but at a cost of increased VUS (8).
Indeed, the ratio of rare VUS to pathogenic or likely
pathogenic cardiomyopathic variants was extremely
unfavorable in our cohort (Figure 2) and illustrated
the need for careful and stringent adjudication.
Nonetheless, through careful use of the ACMG
criteria, we still identiﬁed 6 pathogenic or likely
pathogenic variants in cardiomyopathy genes. This
conﬁrmed ﬁndings of heritable cardiomyopathy in
SADS families following clinical evaluation (6) and
may be due to subtle and perhaps localized struc-
tural disease not noticeable at autopsy or, alterna-
tively, to effects of genetic variation in these genes
on cardiac electrical function before the onset of
cardiomyopathic changes. For example, electro-
physiological changes, including a decreased sodium
current, were observed in the absence of overt car-
diomyopathy in mouse models of desmosomal
arrhythmogenic cardiomyopathy (33,34).
STUDY LIMITATIONS. In most SADS cases included in
this study (220 of 302; 73%) we were not able to
perform comprehensive clinical evaluation of rela-
tives. Therefore, the combined value of genetic
testing and clinical evaluation of relatives could only
be assessed in 82 families. Antemortem data were
missing in 40 cases, which may have affected geno-
type and phenotype correlations minimally. While
included cases were either consecutive referrals or
from population studies, we recognize that there may
be an element of referral bias.
A small number of genotype-positive LQTS cases
from New Zealand were not included in the study
(13,14). Of these, only 3 would have been adjudicated
as pathogenic or likely pathogenic by ACMG criteria
and would not have affected the yield signiﬁcantly. In
addition, some exons were moderately covered (e.g.,
exon 1 of KCNQ1 and KCNH2 in cohort 1) (Online
Table 3), but this was unlikely to have resulted in
signiﬁcant underestimation of the yield. Interpreta-
tion of variants in the small minority of non-
Caucasian cases may have been hampered by the
absence of large, ethnically speciﬁc population data-
bases to which we could refer. Furthermore, we did
not sequence genes currently associated with
noncardiac disorders that predispose to sudden
death.
CONCLUSIONS
Next-generation sequencing based molecular au-
topsy identiﬁed a 13% yield of clinically actionable
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Post-
mortem genetic testing can establish a molecular diag-
nosis in a substantial minority of cases of SADS. When
combined with clinical evaluation of relatives, such
testing increases the diagnostic yield to approximately
40%, but most cases of SADS cannot be explained by
clinically detectable genetic disorders in familymembers.
TRANSLATIONAL OUTLOOK: Future research into
the causes of SADS should include not only family and
functional studies but also nongenetic and noncardiac
etiologies such as neurological disease and environ-
mental triggers of arrhythmias.
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2144rare variants in SADS cases. This required the
application of a stringent allele frequency threshold
and ACMG guidelines to achieve robust, clinically
useful results. Furthermore, its systematic use,
combined with clinical and genetic evaluation of
families, enhanced diagnostic utility. Our data also
highlighted the important role of RYR2 in SADS.
Molecular autopsy should, however, not be limited
to only young cases, as the yield is independent of
age at death.
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